natgillin/translations-raw huggingface dataset:
The compound is characterized by direct comparison with a reference compound by HPLC. 
Spoj je karakteriziran izravnom usporedbom sa referentnim spojem pomoću HPLC.
FIG. 2 compares the glucose consumption rate obtained when cultivating cells using non-recycled Fibra-Cel® disks (gray squares) or using Fibra-Cel® disks recycled according to a method of the present invention (black triangles). 
Slika 2. prikazuje stopu potrošnje glukoze koja je dobivena kada se uzgajaju stanice rabeći diskove Fibra-Cel* koji se ne recikliraju (sivi kvadratići) ili rabeći diskove Fibra-Cel* koji se recikliraju sukladno postupku iz ovoga izuma (crni trokutići).
sieving the active ingredient, the stabilizing additive and/or stabilizing additives and the excipients, 
prosijavanje aktivnog sastojka, dodatka za stabilizaciju i/ili dodataka za stabilizaciju i ekscipijenata;
providing at least one targeting endonuclease or a first nucleic acid molecule comprising a nucleic acid sequence encoding the at least one targeting endonuclease, wherein the at least one targeting endonuclease(s) recognize the at least one targeting endonuclease recognition site introduced into the genome of the transgenic plant; 
pripravljanje najmanje jedne ciljne endonukleaze ili prve molekule nukleinske kiseline koja obuhvaća sekvencu nukleinske kiseline koja kodira najmanje jednu ciljnu endonukleazu, pri čemu najmanje jedna ciljna endonukleaza prepoznaje najmanje jedno mjesto prepoznavanja ciljne endonukleaze koja je uvedena u genom transgene biljke;
a method of treating a subject for cancer refractory to a standard treatment, the method comprising administering to the subject a therapeutically effective amount of the first agent and the one or more second agents; 
liječenju raka u subjekta čiji je rak refraktoran na standarni režim liječenja, koje obuhvaća primjenu terapijski učinkovite količine spoja formule VIII subjektu;
Embodiment 215 A method according to embodiment 213, wherein the one or more further therapeutic agents are selected from a group consisting of cisplatin, gefitinib, cetuximab, rituximab, bevacizumab, erlotinib, bortezomib, thalidomide, pamidronate, zoledronic acid, clodronate, risendronate, ibandronate, etidronate, alendronate, tiludronate, arsenic trioxide, lenalidomide, filgrastim, pegfilgrastim, sargramostim, suberoylanilide hydroxamic acid, and SCIO-469. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevom 22, naznačena time što je jedno ili više daljnjih terapijskih sredstava odabrano iz skupino koja se sastoji od cisplatina, gefitiniba, cetuksimaba, rituksimaba, bevacizumaba, erlotiniba, bortezomiba, talidomida, pamidronata, zoledronske kiseline, klodronata, porandronata, ibandronata, etidronata, alendronata, tiludronata, arsenovog trioksida, lenalidomida, filgrastima, pegfilgrastima, sargramostima, suberoilanilid- hidroksamične kiseline i SCIO-469.
allowing the antibody to bind to any amyloid protein in the sample to form an immunologic complex; 
(b) omogućavanja da se protutijelo veže na sve amiloidne proteine u uzorku kako bi tvorilo imunološki kompleks;
A door lock according to claim 1, wherein the body part and the shaft are a solid integral part. 
Brava prema jednom od zahtjeva 3 ili 4 naznačena time da tijelo brave (22) i njegovo vratilo (29) predstavljaju jednu cjelinu.
conjugating the capsular polysaccharide obtained in a) to a carrier protein, 
- b) kapsularni polisaharid koji je dobiven u koraku a) je konjugiran na protein nosač.
The solar cell according to claim 1, wherein the second layer is formed from a material other than SiN, and wherein the first layer has a refractive index n of n≧2.0. 
Solarna ćelija u skladu s najmanje jednim od prethodnih patentnih zahtjeva, naznačena time što u slučaju dobivanja drugog sloja iz materijala koji nije SiN, prvi sloj ima indeks loma od n > 2,0, ili u slučaju dobivanja drugog sloja (26) iz SiN ili kada sadrži SiN, indeks loma prvog sloja je manji od onog kod drugog sloja.
The compound of paragraph 5 wherein X is an optionally substituted phenyl group which can be optionally substituted, wherein the substituents are selected from C1-C4 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, C1-C4 alkoxy, CF3, carboxy, alkoxyalkyl, C1-C4 cycloalkylalkoxy, amino, alkylamino, dialkylamino, amido, alkylamido, dialkylamido, thioalkyl, halogen, cyano, alkylsulfonyl and nitro. 
Spoj prema bilo kojem od zahtjeva 1-2, naznačen time da je X opcionalno supstituirana skupina fenila, naznačen time da se ti supstituenti biraju iz skupine koju sačinjavaju Ci-Ca alkil, C3-Cg cikloalkil, Cz-Cg cikloalkiloksi, Cj-Ca alkoksi, CF, karboksi, alkoksialkil, Cy-C, cikloalkilalkoksi, amino, alkilamino, dialkilamino, amido, alkilamido, dialkilamido, tioalkil, halogen, cijano, alkilsulfonil 1 nitro.
V is selected from the group consisting of S, SO2, SO, O or NH; 
V se bira iz skupine koju čine S, SO2, SO, O ili NH;
The pharmaceutical composition as claimed in claim 15, which comprises, as a further active ingredient, one or more antidiabetic agents, active hypoglycemic ingredients or anti-hypertension agents. 
Farmaceutski pripravak prema zahtjevu 15, naznačen time da, kao dodatni aktivni sastojak, sadrži, jedno ili više antidijabetičkih sredstava, aktivne hipoglikemijske sastojke ili anti-hipertenzijska sredstva.
This particularly applies if the machining elements have cutting edges which are essentially in parallel to the rotational plane of the rotational solid. 
To se naročito primjenjuje, ako elementi za strojnu obradu imaju bridove za rezanje koji su uglavnom paralelni s ravninom rotacije. Slika 1
Fig. 4 is a perspective view of the parts making up the building floor. 
je prostorni pogled dijelova koji tvore pod građevine.
The communication device according to claim 12 wherein the pair of DVRBs assigned by the single resource block number are mapped to PRBs that are different in a time domain. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
A counter as described in embodiment 14, wherein said third ring member comprises a limiting mechanism to limit free rotation of said second ring member relative to said third ring member about said common axis. 
Brojač kao što je navedeno u zahtjevu 15, naznačeno time da navedeni treći prstenasti element (1502) sadrži mehanizam ograničenja (1506) za ograničavanje slobodne rotacije navedenog drugog prstenastog elementa (202, 1510) u odnosu na navedeni treći prstenasti element oko navedene zajedničke osi.
Enzyme-composition comprising at least one cellulase, at least one hemicellulase and at least one pectinase, wherein the at least one hemicellulase comprises an Arabinan endo-1,5-alpha-L-arabinosidase (EC 3.2.1.99) with an arabinan degrading activity of from 10 to 100 U/mg protein, wherein the arabinan degrading activity of the Arabinan endo-1,5-alpha-L-arabinosidase (EC 3.2.1.99) is 8 to 100 times as much as the cellulose degrading activity of the at least one cellulase, wherein the arabinan degrading activity of the Arabinan endo-1,5-alpha-L-arabinosidase (EC 3.2.1.99) is 10 to 250 times as much as the pectin degrading activity of the at least one pectinase, and wherein when another hemicellulase is present in the composition the arabinan degrading activity of the Arabinan endo-1,5-alpha-L-arabinosidase (EC 3.2.1.99) is 0.25 to 5 times as much as the hemicellulose degrading activity of the at least one hemicellulase. 
HR P20181192 T1 PATENTNI ZAHTJEVI Spoj enzima koji sadrži bar jednu celulazu, bar jednu hemicelulazu i bar jednu pektinazu pri čemu bar jedna hemicelulaza sadrži Arabinansku endo-1,5-alfa-L-arabinozidazu (EC 3.2.1.99) s razgrađujućim djelovanjem na arabinan od 10 do 100 U/mg proteina, naznačen time da je razgrađujuće djelovanje na arabinan Arabinanske endo-1,5-alfa-L-arabinozidaze (EC 3.2.1.99) & do 100 puta jače od razgrađujućeg djelovanja na celulozu bar jedne celulaze pri čemu je razgrađujuće djelovanje na arabinan Arabinanske endo-1,5-alfa-L-arabinozidaze (EC 3.2.1.99) 10 do 250 jače od razgrađujućeg djelovanja na pektin bar jedne pektinaze i pri čemu je, kad je još jedna hemicelulaza prisutna u spoju, razgrađujuće djelovanje na arabinan Arabinanske endo-1,5-alfa-L-arabinozidaze (EC 3.2.1.99) 0.25 do 5 puta jače od razgrađujućeg djelovanja na hemicelulozu bar jedne hemicelulaze.
m is an integer 0-2; n is an integer from 1 to 5; 
m je cijeli broj u rasponu 0 - 2; n je cijeli broj u rasponu od 1 do 5;
The mixture was stirred for 1 hour and then filtered through 24 cm fluted filter paper into a 2L 3-N round bottom flask. The Na2SO4 solids were washed with DCM (100mL) into the flask. 
Smjesa je bila miješana kroz 1 sat i tada filtrirana kroz papirnati filtar s utorima od 24 cm u 2 L 3-N tikvicu s okruglim dnom Kruti Na»SO, bio je ispran s DCM (100 mL) u tikvicu.
The offshore aquaculture system of claim 1, wherein the framework is of the vertical dimension of the cages and the positioning apparatus is arranged to allow movement of the cages between an upper position in which the cages are vertically contained within the framework and a lower position in which the cages are positioned below the framework. 
Sustav odobalne akvakulture prema zahtjevu 1, pri čemu se okvir (120) podudara s visinom rešetaka (130), a uređaj za pozicioniranje (140) je postavljen tako da dopušta pomicanje rešetaka između gornjeg položaja u kojem se rešetke nalaze unutar okvira i donjeg položaja u kojem se rešetke nalaze ispod njega.
a cable entry board; a hollow cylindrical tube formed on the cable entry board; 
prvu šuplju cilindričnu cijev (52, 63, 83) koja je oblikovana na ploči za ulaz kabela (51, 61, 81);
projecting a cross-grid over the image, wherein the grid has a grid distance adapted to observe the austenite-ferrite phase boundaries; 
Projiciranje rešetke preko slike, pri čemu su polja rešetke prikladna za promatranje granica austenitne faze;
No. 10/140,596 and WO 99/58253, instead uses a palm or hand-sized APPLI-PRO™ container or bottle (see U.S. Pat. No. D409,303) of concentrated inoculant pre-mix that could be removably installed to its spraying system. 
10/140,596 1 WO 99/58253, koristi jednu APPLI-PROTM posudu ili bocu, veličine da može stati u dlan ili šaku, (vidjeti U.S. Patent D409,303) koncentrirane prethodne mješavine inokulanta koja se može odvojivo ugraditi u sustav za raspršivanje.
Combination according to claim 2, characterized in that the auto-immune disease is rheumatoid arthritis, glomerulonephritis, multiple sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or psoriasis. 
Kombinacija sukladno patentnom zahtjevu 2, naznačena time, da je autoimuna bolest reumatoidni artritis, glomeruloneftitis, multipla skleroza, Crohnova bolest, ulcerozni kolitis, sistemski lupus eritematosus ili psorijaza.
In a preferred embodiment of the invention a resin of a relatively high functionality (OH>3 mol/mol) and yet a low polarity is used as component A and rapeseed oil methyl ester (RME) used as component C. The coating is then applied on to a substrate and cured by heat activation. Suitable substrates for the coating are any material that can sustain a heat activated curing. 
U izvedbi izuma, kojoj se daje prednost, kao komponenta A upotrebljava se smola relativno visoke funkcionalnosti (OH > 3 mola/molu) i k tome niske polarnosti, te metil ester repičinog ulja (RME, e. rapeseed oil methyl ester) kao komponenta C. Zatim se premaz nanosi na podlogu i otvrdnjava se toplinskom aktivacijom.
Object of the present invention are: 
Broj objave europskog patenta:
where n = 5 to 9 and X is I, Br, Cl or mesyl, under the treatment of the organic base in tetrahydrofuran under an argon atmosphere at the temperature of -78°C, condensates with aldehyde of the formula III,, affording the silylated derivative of the general formula IV, where n = 5 to 9, and silylated derivative of the general formula IV is treated with tetrabutylammonium fluoride affording alkenol of the general formula V, where n = 5 to 9, which is reduced in the hydrogen atmosphere in the presence of a catalyst to alcohol of the general formula VI, where n = 5 to 9, alcohol of the general formula VI is substituted to appropriate derivative of the general formula VII, 
Način pripreme alkil trifenil fosfonijskih derivata tamoksifena opće formule I prema zahtjevu 1 odlikuje se time, da ylid generirani iz tert-butildimefilsili-oksi-alkil-trifenil fosfonija opće formule II, II, gdje n = 5 do 9 i X je I, Br, Cl ili mesil, u tetrahidrofuranu u atmosferi argona na temperaturi -78°C djelovanjem organske baze kondenzira s aldehidom formule III, III, pri nastanku siliranog derivata opće formule IV, IV, gdje n = 5 do 9 na silirani derivat opće formule IV djeluje tetrabutilamonij fluorid pri nastanku alkenola opće formule V, V, gdje se n = 5 do 9 koji se u atmosferi vodika u prisutnosti katalizatora svodi na alkohol opće formule VI, VI, gdje n = 5 do 9 alkohol opće formule VI se supstitucijom pretvara u odgovarajući derivat opće VII, VII, gdje n = 5 do 9 i X je I, Br, Cl ili mesil, koji se zagrijavanjem s trifenil fosfinom pretvara u mitohondrijalni ciljani alkil trifenil fosfonijski derivat tamoksifena opće formule I.
The binder preferably also contains additives. These include non-hydraulically active substances, for example, ground limestone/dolomite, precipitated CaCO3, Mg(OH)2, Ca(OH)2, silica fume, etc., and they can be metered in an amount ranging from 0.01 to 20% by weight, preferably 0.5 to 15% by weight and even more preferably of 1 to 10% by weight. 
Vezivo sukladno barem jednom od zahtjeva 3 do 6, naznačeno time što dodatno sadrži hidraulički reaktivne materijale, poput Portland cementa i/ili ne hidraulički reaktivne materijale, poput mljevenog vapnenca/dolomita, istaloženog CaCO:s, Ca(OH) 2, Me(OH) 2, silikonskog dima raspona od 1 do 30 % mase, poželjno od 5 do 20 % mase.
at least one collecting line (15) coupled between said at least one mobile suction means (5) and said at least one filtration means (3); 
filtriranje protoka usisanog mobilnim sredstvom za usisavanje (5), najmanje jednim sredstvom za filtriranje (3); i
for compounds of formula I wherein A represents S, W represents -[CRxRy]m- and m represents 0, reaction of a compound of formula III as hereinbefore defined with a compound of formula V, L3-D V wherein L3 is a suitable leaving group and D is as defined in Claim 1; 
za spojeve s formulom I pri čemu A predstavlja S, W predstavlja -[CRxRy]m- i m predstavlja 0, reakcijom spoja s formulom III kao što je definirano u daljnjem tekstu sa spojem s formulom V, -D V pri čemu L3 je prikladna izlazna skupina i D je kako je definirano u zahtjevu 1;
The use of an anti-NogoA antibody, functional fragment or analogue thereof according to any one of claims 1 to 8, in the preparation of a medicament for treatment of stroke, traumatic brain injury, spinal cord injury, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease or multiple sclerosis in a human. 
Upotreba protutijela protiv Nogo-A, ili njegovog funkcionalnog fragmenta ili analoga, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, u pripravi medikamenta za liječenje inzulta, traumatske ozljede mozga, ozljede kralježničke moždine, Alzheimerove bolesti, fronto-temporalnih demencija (tauopatija), periferne neuropatije, Parkinsonove bolesti, Huntingtonove bolesti ili multiple skleroze kod čovjeka.
Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting in vitro T cells with antigen loaded human MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The composition according to claim 4, which composition is a multiparticulate composition in which substantially each particle is enteric coated. 
Sastav u skladu s patentnim zahtjevom 4, gdje je sastav višečestični sastav u kojemu je sadržajno svaka čestica enterično obložena.
The method of claim 37, wherein the pH of the inner coating preparation is adjusted to be from about pH 7.5 to about pH 10. 
Postupak sukladno patentnim zahtjevima 11 do 13, naznačeno time, da je pH unutarnjeg pripravka za oblaganje podešen da bude od pH 7,5 do pH 10, poželjno od pH 7,5 do pH 5,5, poželjnije oko pH 8.
The homogenizate was moistened with a mixture of a solution of 0.04 kg of xanthane gum in 6.5 kg of ion-exchanged water and 1.0 kg of 39% dimethyl polysiloxane. 
Homogenizat je navlažen sa smjesom otopine 0,04 kg ksantanske gume u 6,5 kg ionsko-izmjenjivačke vode i 1,0 kg 39% dimetil polisiloksana.
A prodrug selected from the group consisting of wherein m is an integer from 200 to 250 and n is an integer from 100 to125; wherein n is an integer from 400 to 500; wherein n is an integer from 400 to 500; and wherein n is an integer from 400 to 500. 
16. Predlijek, naznačen time, da je odabran iz skupine koju čine: pri čemu je m cijeli broj od 200 do 250, dok je n cijeli broj od 100 do 125;
The condensation of the substituted tetralone with the appropriate secondary amine NHR1R2 in the presence of an acid catalyst, e.g. TiCl4, yields a 3,4-dihydro-l-dialkylamine compound, which is then reduced to the 1,2,3,4-tetrahydro-l-dialkylamine (mixture of cis- and trans-racemates), e.g. with sodium borohydride in the presence of acetic acid. Certain of the substituted benzophenone starting materials are commercially available, including 4-chlorobenzophenone, 4,4'-dichloro-benzophenone, 4-fluorobenzo- phenone and 4-bromobenzophenone. 
kondenzacija supstituiranog tetralona formule (II) sa sekundarnim aminom (R,; i Rx oba alkil) u prisustvu kiselog katalizatora, npr., TiCL, daje 3,4-dihidro-1-dialkilaminski intermedijer (IV), koje se tada reducira u 1,2,3,4-tetramro-1-dialkilamin (smjesa cis- i trans-recemata), npr., s natrij-borohidridom u prisustvu octene kiseline. HR P930199_B1 B1
According to an embodiment, the swivel member extends along a longitudinal body axis from the first end to the second end of the swivel member, the crane comprising 
Plovilo (4) sukladno Zahtjevu 2, pri čemu se okretni članak (30) proteže duž longitudinalne osi tijela od prvog kraja
System according to one claim 10 or 11, wherein the flash X-ray source (6) is provided with an aperture (16) whose position and/or aperture area (17) can be altered. 
Sustav prema jednom od zahijeva 10 ili 11, pri čemu je predviđen izvor impulsnog rendgenskog zračenja (6) s HR P20120532 TI
Number of subjects 
Broj međunarodne objave:
With reference to Figures 1 and 2, a first embodiment of a breathable and waterproof shoe is generally designated by the reference numeral 10. 
U vezi sa Slikama 1 1 2, prvo utjelovljenje prozračne i vodootporne cipele sukladno predmetnom izumu općenito se označava brojčanom referencom 10.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) ciprodinil.
the thermochromic ink is coloured below the predetermined temperature and becomes colourless when the predetermined temperature is reached or exceeded; and 
(b) navedena termokromna tiskarska boja ima obojenje ispod spomenute predodređene temperature i postaje bezbojna kada se dosegne ili premaši spomenuta predodređena temperatura;
zinc stearate; and/or microcrystalline cellulose. The tablet according to any one of the preceding claims, wherein the tablet is coated with a coating composition. 
Tableta prema bilo kojem od patentnih zahtjeva 2 do 10, naznačena time da pripravak za oblaganje sadrži derivat celuloze, poželjnije hidroksipropilmetilcelulozu, najpoželjnije hidroksipropilmetilcelulozu niskog viskoziteta i/ili hidroksipropilmetilcelulozu visokog viskoziteta.
is selected from the group consisting of hydrogen, chloro, bromo, and fluoro; 
R, je odabran iz skupine koju čine halogen, C,-Cxalkil i CF;;
1 characterised by the fact that ylide generated from tert-butyldimethylsilyl-oxy-alkyl-triphenylphosphonium of the general formula II, 
Način pripreme alkil trifenil fosfonijskih derivata tamoksifena opće formule I prema zahtjevu 1 odlikuje se time, da se na aldehid formule III, no
Preferably, compounds (I) are salified with inorganic or organic acids selected from hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, acetic, trifluoroacetic, propionic, oxalic, malic, maleic, succinic, malonic, aspartic and glutamic acids. 
Spojevi (I) su preferirano prevedeni u soli s anorganksim ili organskim kiselinama odabranih od sljedećih: klorovodična, bromovodična, jodovodična, sumporna, fosforna, octena, trifluoroctena, propionska, oksalna, jabučna, maleinska, jantama, malonska, asparaginska i glutaminska kiselina.
Compound for use according to any one of claims 1 to 6, characterised in that the compound is contained in the medicament in an amount of from 0.1 ng to 10 mg, preferably 10 ng to 1 mg, in particular 100 ng to 100 µg. 
Spoj za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da je spoj kao sastojak lijeka u količini od 0,1 ng do 10 mg, poželjno od 10 ng do 1 mg, najbolje od 100 ng do 100 ug.
the C1-4alkyl or C1-4alkoxy of R0 is unsubstituted or substituted by 1-2 substituents independently selected from C1-4alkoxy, amino, phenyl and C5-6heteroaryl; wherein the phenyl or C5-6heteroaryl substituent of R0 is unsubstituted or further substituted by halo or C1-4alkyl; 
-4alkil ili C1-4alkoksi od R0 nesupstituiran ili supstituiran s 1-2 supstituenta neovisno odabrana iz niza koji čine C1-4alkoksi, amino, fenil i C5-6heteroaril; gdje je fenil ili C5-6heteroarilni supstituent od R0 nesupstituiran ili dalje supstituiran s halo ili C1-4alkilom;
The method according to claim 3, wherein the crystallization solvent is a mixed solvent of ethanol/water, and the anti-solvent is ethanol. 
Postupak sukladno zahtjevu 6, naznačen time što je otapalo za kristalizaciju poželjno miješano otapalo etanol / voda, a protu-otapalo etanol.
Optionally, the level of Zn2+ or Mn2+ is measured from a tissue sample in which case the concentration of Zn2+(or Mn2+) in the lung tissue is less than 20, 15, 10, 5, 2 or 1 ug/g or 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0.5 or 0.1 uM as measured from lung tissue. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u srednjem uhu, a koncentracija Zn"* u srednjem uhu je manja od 300, 200, 150, 100, 50, 20, 10, 5, 2, 1, 0,5, 0,2 ili 0,1 uM.
A compound according to claim 1, wherein R3 is —OCHF2. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu je kožni poremećaj psorijaza.
The surface energy of the tetragonal phase of zirconia is lower than the one of the monoclinic phase at standard temperature and pressure, which results in stable tetragonal (pure) zirconia crystals at room temperature. 
Energija površine tetragonske faze cirkonijeva oksida je niža od monoklinske faze pri standardnoj temperaturi i tlaku, a rezultat su stabilni tetragonski (čisti) kristali cirkonijeva oksida pri sobnoj temperaturi.
In some embodiments, the nucleic acid of the compositions is RNA. 
Nosač transfera prema zahtjevu 2 ili zahtjevu 3, naznačen time što je nukleinska kiselina RNK.